Market Snapshot

S&P Futures
4,141.75
Dow Futures
33,071.00
NASDAQ Futures
14,103.00

5.22$-0.14 -2.61%
At close    04:00 PM   
From: To:

Stock Snapshot

10.79
Prev. Close
5.21
Open
67.34M
Market Cap
461150.00
Number of Shares
5.05
Day Low
5.35
Day High
5.22
-
P/E Ratio
12.03M
Free Float in %
-0.71
EPS 2021
0.96
Book Value per Share
0.94
Cash Flow per Share
Aethlon Medical, Inc. (AEMD)
Aethlon Medical, Inc. (AEMD) stock rallied over -2.61% intraday to trade at $5.22 per share on NASDAQ. The stock opened with a fall of -51.71% at $5.21 and touched an intraday high of $5.35, declining 50.42% against the last close of $10.79. The stock went to a low of $5.05 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-06-18$5.21$5.22$5.22$5.35$5.05806,888
2021-06-17$5.20$5.36$5.36$5.62$5.022,223,600
2021-06-16$5.49$5.27$5.27$5.50$5.002,253,600
2021-06-15$5.95$5.54$5.54$6.20$5.544,152,100
2021-06-14$6.41$5.79$5.79$6.73$5.754,848,200
2021-06-11$6.91$6.49$6.49$7.13$6.2010,216,000
2021-06-10$9.22$6.90$6.90$9.60$6.3725,369,900
2021-06-09$10.60$10.79$10.79$12.49$8.71252,491,200
2021-06-08$2.23$2.21$2.21$2.29$2.157,639,600
2021-06-07$2.21$2.20$2.20$2.30$2.15241,100
2021-06-04$2.27$2.21$2.21$2.37$2.15258,900
Aethlon Medical, Inc.
9635 Granite Ridge Drive
Suite 100
San Diego, CA 92123
United States

http://www.aethlonmedical.com
858 459 7800
Employees
8
Sector
Healthcare
Sales or Revenue
Industry
Medical Devices
5Y Sales Change
-3.10
Fiscal Year Ends
2020-03-30
Dr. Charles J. Fisher Jr.
CEO, Director & Member of Extracorporeal Therapy Advisory Board
Mr. James B. Frakes
CFO, Sr. VP of Fin. & Sec.
Mr. Guy F. Cipriani BS (Eng.), MBA
Sr. VP, Chief Bus. Officer & Director
Aethlon Medical, Inc.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.